| Literature DB >> 29890756 |
Kelsey DeFrates1,2, Theodore Markiewicz3, Pamela Gallo4, Aaron Rack5, Aubrie Weyhmiller6, Brandon Jarmusik7, Xiao Hu8,9,10.
Abstract
Nanoparticles are particles that range in size from about 1⁻1000 nanometers in diameter, about one thousand times smaller than the average cell in a human body. Their small size, flexible fabrication, and high surface-area-to-volume ratio make them ideal systems for drug delivery. Nanoparticles can be made from a variety of materials including metals, polysaccharides, and proteins. Biological protein-based nanoparticles such as silk, keratin, collagen, elastin, corn zein, and soy protein-based nanoparticles are advantageous in having biodegradability, bioavailability, and relatively low cost. Many protein nanoparticles are easy to process and can be modified to achieve desired specifications such as size, morphology, and weight. Protein nanoparticles are used in a variety of settings and are replacing many materials that are not biocompatible and have a negative impact on the environment. Here we attempt to review the literature pertaining to protein-based nanoparticles with a focus on their application in drug delivery and biomedical fields. Additional detail on governing nanoparticle parameters, specific protein nanoparticle applications, and fabrication methods are also provided.Entities:
Keywords: bioimaging; biomaterials fabrication; drug delivery; nanomedicine; nanoparticles; protein
Mesh:
Substances:
Year: 2018 PMID: 29890756 PMCID: PMC6032199 DOI: 10.3390/ijms19061717
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Nanoparticle materials can be fabricated from a variety of protein sources, including silk, keratin, collagen, elastin, soy, and corn zein etc. These proteins can then be processed into particles with unique properties for biomedical applications.
Advantages and disadvantaged of the common protein-based nanoparticle fabrication methods.
| Method | Advantages | Disadvantages |
|---|---|---|
| pH Variation [ |
Control for particle size Control secondary structure of protein Control for zeta potential Produces chemically and physically stable particles Experimentally simple |
Post-fabrication drug loading is required Limited to small scale production |
| Spray-drying [ |
Cost effective Experimentally simple Easily encapsulate hydrophilic drugs Useful for heat-sensitive samples Control for particle size |
Limited to small scale production Challenging to incorporate hydrophobic drugs |
| Rapid Laminar Jet [ |
Control for particle size Production of uniform particles Production of strong, stable particles |
Possibility of coalescence Many parameters must be controlled for |
| Phase Separation [ |
Specialized equipment is not required Particle size can be controlled by adjusting protein concentration Uniform particles are produced |
Particle sizes are limited to 50–500 nm in diameter Organic solvents are required Limited to small scale production |
| Milling [ |
Cost effective Large scale production is possible Control of nanoparticle size Experimentally simple |
Heat is released during the process requiring chamber to be cooled Little control over nanoparticle shape Nanoparticles must be coarse |
| Polymer Chain Collapse [ |
Properties of the nanoparticle can be easily controlled by selection of the precursor chain |
Particle size is limited to 5–20 nm in diameter |
|
Production of particles with high stability Particles with improved spherical shape are produced |
Side reaction may be difficult to control |
Figure 2A schematic of a nanoparticle spray-drying system in which the liquid polymer sample is sprayed alongside of heated gas in a chamber that leads to electrodes which are used to collect the charged sprayed nanoparticles. (Reproduced with permission from [102], Copyright Springer Nature, 2015).
Figure 3This figure shows the basic mechanism used in high energy ball milling. As the cylinder rotates, the milling balls are accelerated and through physical force fracture the polymer material that is placed in the chamber.
Figure 4(A) A model of protein nanosphere. The drug (red) is within a protein matrix (blue); (B) A model of protein nanocapsule. The drug is suspended and encapsulated by a thick protein polymer shell.